143 related articles for article (PubMed ID: 30261804)
1. Estimating age group-dependent sensitivity and mean sojourn time in colorectal cancer screening.
Sung NY; Jun JK; Kim YN; Jung I; Park S; Kim GR; Nam CM
J Med Screen; 2019 Mar; 26(1):19-25. PubMed ID: 30261804
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time.
Launoy G; Smith TC; Duffy SW; Bouvier V
Int J Cancer; 1997 Oct; 73(2):220-4. PubMed ID: 9335446
[TBL] [Abstract][Full Text] [Related]
3. Estimating key parameters in FOBT screening for colorectal cancer.
Wu D; Erwin D; Rosner GL
Cancer Causes Control; 2009 Feb; 20(1):41-6. PubMed ID: 18704710
[TBL] [Abstract][Full Text] [Related]
4. Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches.
Prevost TC; Launoy G; Duffy SW; Chen HH
Am J Epidemiol; 1998 Sep; 148(6):609-19. PubMed ID: 9753016
[TBL] [Abstract][Full Text] [Related]
5. Impact of systematic false-negative test results on the performance of faecal occult blood screening.
Loeve F; Boer R; van Oortmarssen GJ; van Ballegooijen M; Habbema JD
Eur J Cancer; 2001 May; 37(7):912-7. PubMed ID: 11313180
[TBL] [Abstract][Full Text] [Related]
6. Predicting the effectiveness of the Finnish population-based colorectal cancer screening programme.
Chiu SY; Malila N; Yen AM; Chen SL; Fann JC; Hakama M
J Med Screen; 2017 Dec; 24(4):182-188. PubMed ID: 28084889
[TBL] [Abstract][Full Text] [Related]
7. Analysis of screening data: colorectal cancer.
Gyrd-Hansen D; Søgaard J; Kronborg O
Int J Epidemiol; 1997 Dec; 26(6):1172-81. PubMed ID: 9447396
[TBL] [Abstract][Full Text] [Related]
8. Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database.
Brenner H; Altenhofen L; Katalinic A; Lansdorp-Vogelaar I; Hoffmeister M
Am J Epidemiol; 2011 Nov; 174(10):1140-6. PubMed ID: 21984657
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of faecal occult blood tests requested outside the UK National Bowel Cancer Screening Programme.
McDonald R; Tomlins A; Smith S; Harmston C
J Clin Pathol; 2013 Apr; 66(4):330-4. PubMed ID: 23288919
[TBL] [Abstract][Full Text] [Related]
10. Faecal occult blood testing screening for colorectal cancer and 'missed' interval cancers: are we ignoring the elephant in the room? Results of a multicentre study.
George AT; Aggarwal S; Dharmavaram S; Menon A; Dube M; Vogler M; Field A
Colorectal Dis; 2017 May; 19(5):O108-O114. PubMed ID: 27992095
[TBL] [Abstract][Full Text] [Related]
11. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
[TBL] [Abstract][Full Text] [Related]
12. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district.
Grazzini G; Ventura L; Zappa M; Ciatto S; Confortini M; Rapi S; Rubeca T; Visioli CB; Halloran SP
Gut; 2010 Nov; 59(11):1511-5. PubMed ID: 20603498
[TBL] [Abstract][Full Text] [Related]
13. Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening.
Jouve JL; Remontet L; Dancourt V; Lejeune C; Benhamiche AM; Faivre J; Esteve J
Br J Cancer; 2001 Jun; 84(11):1477-81. PubMed ID: 11384097
[TBL] [Abstract][Full Text] [Related]
14. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
Blom J; Törnberg S
J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the long-term effect of FOBT in colorectal cancer screening.
Luo D; Cambon AC; Wu D
Cancer Epidemiol; 2012 Feb; 36(1):e54-60. PubMed ID: 22075536
[TBL] [Abstract][Full Text] [Related]
16. Tailored telephone counselling to increase participation of underusers in a population-based colorectal cancer-screening programme with faecal occult blood test: A randomized controlled trial.
Denis B; Broc G; Sauleau EA; Gendre I; Gana K; Perrin P
Rev Epidemiol Sante Publique; 2017 Feb; 65(1):17-28. PubMed ID: 28089385
[TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer screening: yield of faecal occult blood testing.
Teoh ML; Puvan R; Cheah PY; Yuen Y
Asian Pac J Cancer Prev; 2010; 11(1):153-6. PubMed ID: 20593948
[TBL] [Abstract][Full Text] [Related]
18. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test.
Church TR; Ederer F; Mandel JS
J Natl Cancer Inst; 1997 Oct; 89(19):1440-8. PubMed ID: 9326913
[TBL] [Abstract][Full Text] [Related]
19. A projection of benefits due to fecal occult blood test for colorectal cancer.
Wu D; Erwin D; Rosner GL
Cancer Epidemiol; 2009 Oct; 33(3-4):212-5. PubMed ID: 19733140
[TBL] [Abstract][Full Text] [Related]
20. Interval cancers in a community-based programme of colorectal cancer screening with faecal occult blood test.
Tazi MA; Faivre J; Lejeune C; Bolard P; Phelip JM; Benhamiche AM
Eur J Cancer Prev; 1999 Apr; 8(2):131-5. PubMed ID: 10335459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
